Head and neck cancer

systematic review meta-analysis network meta-analysis

Select immune checkpoint inhibitionInduction chemotherapy All type of patientuncoded clinical condition ***       anti-PD-1docetaxel based induction CTinduction polyCT with platininduction polyCT without platinLarynx preservationother induction CTpaclitaxel based induction CTPF induction CT durvalumab + tremelimumab durvalumabnivolumabpaclitaxelpembrolizumab       2nd lineplatinum failure

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	death (overall survival) (65)complete response to induction CT (17)progression or death (progression free survival PFS) (15)neutropenia (grade 3-4) during induction CT (11)disease free survival (9)Toxic death during induction CT (9)treatment related death (8)larynx preservation (8)complete response to study treatment (8)laryngectomy (7)All grade 3 to 4 events during induction CT (7)cancer related death (6)death of unknown cause (6)death or laryngectomy (5)treatment failure (4)Survival with functional larynx (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	death (overall survival)	complete response to induction CT
immune checkpoint inhibition
nivolumab
Checkmate-141, 2016      NCT	nivolumab	standard treatment	2L	2nd line platinum failure	Risk of bias	conclusive
pembrolizumab
KEYNOTE-040    NCT	pembrolizumab	standard treatment	2L	2nd line	Risk of bias	suggesting
Induction chemotherapy
not classified
Richard (IGR-65), 1974	CT with methotrexate	no induction chemotherapy				negative
Fazekas (RTOG 6801), 1980	CT with methotrexate	no induction chemotherapy				negative
Toohill (MCW-2), 1987	PF	no induction chemotherapy				negative
Lewin (SHNG-85), 1997	PF	no induction chemotherapy				negative
Paccagnella (GSTTC-86 ), 1994	PF	no induction chemotherapy				negative
Domenge (GETTEC neo1), 1995	PF	no induction chemotherapy				negative
Domenge (GETTEC), 2000	PF	no induction chemotherapy				negative
Dalley (AHNTG), 1995	PF	no induction chemotherapy				negative
Tejedor (Las Palmas), 1992	PF	no induction chemotherapy				negative
Gedouin (Rennes-87), 1996	PF	no induction chemotherapy				negative
Di Blasio (Parma), 1994	PF	no induction chemotherapy				negative
Depondt (CFHNS), 1993	PF	no induction chemotherapy				negative
Volling (Cologne), 1994	PF	no induction chemotherapy				negative
Hasegawa (HNAP-02), 1996	PF	no induction chemotherapy				-
BNH 003	PF	no induction chemotherapy				negative
Hareyama, 2002	PF	no induction chemotherapy				-
RTOG 91-11 (I+RT vs RT alone), 2003	PF	no induction chemotherapy				suggesting
Licitra, 2003      NCT	PF	no induction chemotherapy				negative
EORTC 24844	PF	no induction chemotherapy				negative
Carugati (Buenos Aires ), 1988	polyCT with platin	no induction chemotherapy				negative
Mazeron (Créteil-82), 1992	polyCT with platin	no induction chemotherapy				negative
Brunin (HNCGIC02), 1989	polyCT with platin	no induction chemotherapy				negative
Salvajoli (AC Camargo), 1992	polyCT with platin	no induction chemotherapy				negative
Jaulerry Trial 2 (Curie)(HNCGIC03), 1992	polyCT with platin	no induction chemotherapy				negative
Maipang (Songkla), 1995	polyCT with platin	no induction chemotherapy				negative
Kohno, 2000	polyCT with platin	no induction chemotherapy				negative
HNCP, 1987	polyCT with platin	no induction chemotherapy				negative
Schuller (SWOG 8006), 1988	polyCT with platin	no induction chemotherapy				negative
Szpirglas (Pitié-81 ), 1988	polyCT with platin	no induction chemotherapy				negative
Jortay (EORTC 24771), 1990	polyCT without platin	no induction chemotherapy				negative
Richard (EORTC 78-OCP), 1991	polyCT without platin	no induction chemotherapy				negative
Holoye (MCW-1), 1985	polyCT without platin	no induction chemotherapy				negative
Chauvergne, 1988	polyCT with platin	cisplatin				negative
De Andres, 1995	carboplatin, 5FU	PF				negative
Clark (Dana farber cancer Institute 83-084), 1988	PBM	PF				negative
Fonseca, 2005	TP	PF				negative
EORTC 24971 (TAX 323), 2006        NCT	TPF	PF				suggesting
GORTEC 2000-01      NCT	TPF	PF				suggesting
TAX324 (Larynx preservation subset), 2007    NCT	TPF	PF				-
Posner (TAX324), 2007      NCT	TPF	PF				suggesting
Prévost, 2005	VP16 based CT	PF				negative
Fonseca, 1997	PF with leucovorin	PF without leucovorin				negative
GETTEC, 1998	induction PF	surgery				suggesting
Veterans Affairs, 1998	induction PF	surgery				suggesting
EORTC 24891, 1996	induction PF	surgery				suggesting
paclitaxel
Hitt paclitaxel, 2005	paclitaxel based CT	PF				suggesting